Superworth

ImageneBio free cash flow IMA

Cash from operations less capital spending, by quarter and over the last twelve months, from 2020.

Last 12 months, to Dec 31, 2023
−$80.2M
Latest quarter, Q4 FY23
−$22.1M
Fiscal year 2023
−$80.2M

ImageneBio's free cash flow was −$80.2M over the twelve months to Dec 31, 2023.

In its latest quarter, Q4 FY23, it was −$22.1M.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2023−$80.2Mn/a
FY2022−$75.5Mn/a
FY2021−$62Mn/a
FY2020−$38.6Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY23−$22.1Mn/a−$80.2M
Q3 FY23−$20Mn/a−$76M
Q2 FY23−$18.1Mn/a−$74.3M
Q1 FY23−$19.9Mn/a−$75.7M
Q4 FY22−$17.9Mn/a−$75.5M
Q3 FY22−$18.4Mn/a−$71.6M
Q2 FY22−$19.5Mn/a−$71.4M
Q1 FY22−$19.8Mn/a−$67.8M
Q4 FY21−$13.9Mn/a−$62M
Q3 FY21−$18.2Mn/a−$61.3M
Q2 FY21−$15.9Mn/a−$50.8M
Q1 FY21−$14Mn/a−$42.6M

Against its peers

Companies in Healthcare nearest ImageneBio's size, closest first, today.

CompanyFree cash flow yield
IMAImageneBion/m
ATNMActinium Pharmaceuticalsn/m
APTAlpha Pro Tech10.3%
NEPHNephrosn/m
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
ICCCImmucell4.5%
KEQUKewaunee Scientific11.5%
PDEXPro DEX3.4%
PLXProtalix BioTherapeutics3.7%
NATRNatures Sunshine Products8.5%
Peer median8.5%

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on ImageneBio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.